Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2289335 | 0.87 | ALDH1A1 (0.46) | NOTUMHDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL892162 | 0.87 | PTPN1 (0.44) | NOTUMHDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL892180 | 0.83 | PTPN1 (0.52) | NOTUMHDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL892936 | 0.82 | NOTUM (0.52) | NOTUMHDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL7818940 | 0.81 | SLC6A2 (0.54) | NOTUMHDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL7433338 | 0.80 | HTT (0.52) | NOTUMHDAC1HDAC8HDAC6SLC6A2 | |
| SCHEMBL893097 | 0.79 | PTPN1 (0.46) | PTPN1ALDH1A1CYP2C19 | |
| SCHEMBL892698 | 0.79 | TSHR (0.55) | NOTUMHDAC6PTPN1ALDH1A1 | |
| SCHEMBL308869 | 0.78 | PTPN1 (0.59) | NOTUMHDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL891655 | 0.77 | TSHR (0.47) | PTPN1CYP2D6ALDH1A1CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | NOTUM 4676/4885HDAC1 1713/4885HDAC8 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.